WHAT IS CLAIMED:

1. Use of a compound 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, or a stereoisomer or mixture of stereoisomers, pharmaceutically acceptable salt, tautomer, prodrug, solvate, hydrate, co-crystal, clathrate, or polymorph thereof (Compound 1) in the manufacture of a medicament for treating acute myeloid leukemia, wherein the medicament is for administration in combination with 1) a therapeutically effective amount venetoclax and a therapeutically effective amount azacitidine or 2) a therapeutically effective amount a FLT3 inhibitor.

2. The use of claim 1, wherein the medicament is for administration in combination with a therapeutically effective amount venetoclax and a therapeutically effective amount azacitidine.

3. The use of claim 2, wherein the FLT3 inhibitor is gilteritinib.

4. The use of any one of claims 1-3, wherein the acute myeloid leukemia is refractory or relapsed acute myeloid leukemia.

5. The use of any one of claims 1-4, wherein the compound is to be administered in a dose of about 0.1 mg to about 10 mg.

6. The use of any one of claims 1-5, wherein the dose is about 0.3 mg, 0.6 mg, 1.2 mg, 1.8 mg, 2 mg, 2.4 mg, 3 mg/day, 3.6 mg, 4.5 mg/day, 5.4 mg or 8.1 mg.

7. The use of any one of claims 1-2 and 5-6, wherein the therapeutically effective amount of venetoclax is about 400 mg.

8. The use of any one of claims 1-2 and 5-6, wherein the therapeutically effective amount of azacitidine is about 75 mg/m^2.

9. The use of any one of claims 1, 3 and 5-6, wherein the therapeutically effective amount of gilteritinib is about 120 mg.

10. The use of any one of claims 1-9, wherein the compound is to be administered in one or more treatment cycles.

11. The use of claim 10, wherein each treatment cycle is a 28 day cycle.

12. The use of any one of claims 1-11, wherein Compound 1 is to be administered once daily on days 1 to 5 of the 28 day treatment cycle.

13. The use of any one of claims 1-12, wherein Compound 1 is to be administered once daily on days 4 to 8 of the 28 day treatment cycle.

14. The use of claim 12 or 13, wherein the treatment cycle is to be repeated at least once.

15. The use of claim 14, wherein the treatment cycle is to be repeated 2 to 6 times.

16. The use of claim 1 or 2, wherein Compound 1, venetoclax and azacitidine are to be administered in two or more 28 day cycles as follows:

in cycle 1, 1.2 mg Compound 1 is to be administered once daily on days 4-8, 75 mg/m^2 azacitidine on days 1-7, 100 mg venetoclax on day 1, 200 mg venetoclax on day 2, and 400 mg venetoclax on days 3-28; and

in subsequent cycles, 1.2 mg Compound 1 is to be administered once daily on days 1-5, 75 mg/m^2 azacitidine on days 1-7, and 400 mg venetoclax once daily on days 3-28.

17. The use of claim 1 or 2, wherein Compound 1, venetoclax and azacitidine are to be administered in two or more 28 day cycles as follows:

in cycle 1, 2 mg Compound 1 is to be administered once daily on days 4-8, 75 mg/m^2 azacitidine on days 1-7, 100 mg venetoclax on day 1, 200 mg venetoclax on day 2, and 400 mg venetoclax on days 3-28; and

in subsequent cycles, 2 mg Compound 1 is to be administered once daily on days 1-5, 75 mg/m^2 azacitidine on days 1-7, and 400 mg venetoclax once daily on days 3-28.

18. The use of claim 1 or 2, wherein Compound 1, venetoclax and azacitidine are to be administered in two or more 28 day cycles as follows:

in cycle 1, 3 mg Compound 1 is to be administered once daily on days 4-8, 75 mg/m^2 azacitidine on days 1-7, 100 mg venetoclax on day 1, 200 mg venetoclax on day 2, and 400 mg venetoclax on days 3-28; and

in subsequent cycles, 3 mg Compound 1 is to be administered once daily on days 1-5, 75 mg/m^2 azacitidine on days 1-7, and 400 mg venetoclax once daily on days 3-28.

19. The use of claim 1 or 3, wherein the Compound 1 and gilteritinib are to be administered in one or more 28 day cycles, in each cycle 1.2 mg Compound 1 is to be administered once daily on days 1-5 and 120 mg gilteritinib on days 1-28.

20. The use of claim 1 or 3, wherein the Compound 1 and gilteritinib are to be administered in one or more 28 day cycles, in each cycle 2 mg Compound 1 is to be administered once daily on days 1-5 and 120 mg gilteritinib on days 1-28.

21. The use of claim 1 or 3, wherein Compound 1 and gilteritinib are to be administered in one or more 28 day cycles, in each cycle 3 mg Compound 1 is to be administered once daily on days 1-5 and 120 mg gilteritinib on days 1-28.

22. The use of any one of claims 1-21, wherein the compound is to be administered with one or more of calcium, calcitriol, or vitamin D supplementation.

23. The use of any one of claims 1-21, wherein one or more of calcium, calcitriol, or vitamin D supplementation is to be administered prior to Compound 1.

24. The use of any one of claims 1-21, wherein one or more of calcium, calcitriol, or vitamin D supplementation are to be administered at least 3 days prior to Compound 1 on day 1 of the cycle.

25. The use of any one of claims 22-24, wherein the patient does not have a disorder disrupting normal calcium homeostasis or preventing calcium supplementation.

26. The use of any one of claims 1-25, wherein the compound is be administered further with a therapeutically effective amount of another additional active agent or a supportive care therapy.

27. The use of claim 26, wherein the other additional active agent is selected from a hematopoietic growth factor, a cytokine, anti cancer agent, an antibiotic, a cox-2 inhibitor, an immunomodulatory agent, an immunosuppressive agent, a corticosteroid or a pharmacologically active mutant or derivative thereof and a therapeutic antibody that specifically binds to a cancer antigen.

28. The use of any one of claims 1-27, wherein the second additional active agent is selected from a group consisting of a glucocorticoid receptor agonist, an interleukin-1 receptor antagonist, an interleukin-1β blocker and a vasopressor.